CL
BLUE

Croft-Leominster’s bluebird bio BLUE Stock Holding History

Croft-Leominster’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-463
Closed -$368K – 127
2016
Q3 		$406K Hold
463
– – 0.1% 93
2016
Q2 		$259K Hold
463
– – 0.06% 142
2016
Q1 		$255K Buy
+463
New +$284K 0.06% 143

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Croft-Leominster's BLUE Position: Q4 2016 in Review

Croft-Leominster sold out of bluebird bio (BLUE) in Q4 2016, closing a stake of 463 shares — an estimated $368K sold.

Croft-Leominster first reported a position in BLUE in Q1 2016 and held it in 3 quarters. The position peaked at $406K in Q3 2016. 199 funds tracked by Wall St. Rank hold BLUE as of Q4 2016.

  • Croft-Leominster reported no remaining bluebird bio position as of Q4 2016 after selling out during the quarter.
  • Croft-Leominster sold 463 bluebird bio shares in Q4 2016, an estimated $368K.
  • Croft-Leominster first reported a position in bluebird bio in Q1 2016 and held it in 3 quarters.
  • Croft-Leominster's bluebird bio position peaked at $406K in Q3 2016.
  • 199 funds tracked by Wall St. Rank held bluebird bio as of Q4 2016.

Based on Croft-Leominster's 13F filing for Q4 2016, filed 15 Feb 2017.